Company Analysis Jiang Zhong Pharmaceutical Co.,Ltd
1. Summary
Advantages
- The company's current efficiency (ROE=20.49%) is higher than the sector average (ROE=3.09%)
Disadvantages
- Price (21.98 Β₯) is higher than fair price (16.04 Β₯)
- Dividends (0%) are below the sector average (1.18%).
- The stock's return over the last year (5.17%) is lower than the sector average (6.59%).
- Current debt level 0.0461% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Jiang Zhong Pharmaceutical Co.,Ltd | Healthcare | Index | |
---|---|---|---|
7 days | -3% | -5.6% | -1% |
90 days | -5.4% | -0.5% | 4.4% |
1 year | 5.2% | 6.6% | 34.7% |
600750 vs Sector: Jiang Zhong Pharmaceutical Co.,Ltd has slightly underperformed the "Healthcare" sector by -1.43% over the past year.
600750 vs Market: Jiang Zhong Pharmaceutical Co.,Ltd has significantly underperformed the market by -29.56% over the past year.
Stable price: 600750 is not significantly more volatile than the rest of the market on "Shanghai Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 600750 with weekly volatility of 0.0994% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (21.98 Β₯) is higher than the fair price (16.04 Β₯).
Price is higher than fair: The current price (21.98 Β₯) is 27% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.9) is lower than that of the sector as a whole (118.47).
P/E vs Market: The company's P/E (17.9) is lower than that of the market as a whole (69.67).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.16) is lower than that of the sector as a whole (5.76).
P/BV vs Market: The company's P/BV (3.16) is higher than that of the market as a whole (3.05).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.18) is lower than that of the sector as a whole (16.9).
P/S vs Market: The company's P/S indicator (3.18) is lower than that of the market as a whole (6.29).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (12.84) is lower than that of the sector as a whole (16.62).
EV/Ebitda vs Market: The company's EV/Ebitda (12.84) is lower than that of the market as a whole (17.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 13.28% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (13.28%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (3.16%).
5.4. ROE
ROE vs Sector: The company's ROE (20.49%) is higher than that of the sector as a whole (3.09%).
ROE vs Market: The company's ROE (20.49%) is higher than that of the market as a whole (6.26%).
5.5. ROA
ROA vs Sector: The company's ROA (12.47%) is higher than that of the sector as a whole (3.37%).
ROA vs Market: The company's ROA (12.47%) is higher than that of the market as a whole (3.28%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.18%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.71.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (97.5%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription